Emanuela Palmerini, MD, Istituto Ortopedico Rizzoli, Bologna, Italy, outlines observations made in the GRACefUl (NCT05357768) study which focused on undifferentiated small round cell sarcomas (URCSs). The study further subdivided this category into CIC-rearranged round cell sarcomas, BCOR::CCNB3-rearranged round cell sarcomas, and unclassified URCSs based on molecular assessment. It differentiated the unique characteristics, demographic, clinical behavior, response rates and survival outcomes of each URCS subtype. While treatments are similar at present, their distinct profiles require the development of diverse clinical approaches. Next-generation sequencing (NGS) data may prove a useful tool for predicting the effectiveness of various therapeutic methods. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
